CapsoVision, Inc. (CV)
| Market Cap | 337.91M |
| Revenue (ttm) | 13.55M |
| Net Income (ttm) | -25.32M |
| Shares Out | 49.84M |
| EPS (ttm) | -1.03 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 167,615 |
| Open | 6.78 |
| Previous Close | 6.37 |
| Day's Range | 6.40 - 6.98 |
| 52-Week Range | 3.43 - 15.37 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 10.00 (+47.49%) |
| Earnings Date | May 20, 2026 |
About CV
CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon). It also provides CapsoCloud cloud-based software-as-a-service ecosystem as a... [Read more]
Financial Performance
In 2025, CapsoVision's revenue was $13.55 million, an increase of 15.29% compared to the previous year's $11.76 million. Losses were -$25.32 million, 27.2% more than in 2024.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for CV stock is "Buy" and the 12-month stock price target is $10.0.
News
CapsoVision Earnings Call Transcript: Q4 2025
Revenue grew 15% year-over-year in 2025, driven by CapsoCam Plus adoption and new account growth. AI-enabled product pipeline advanced, with pivotal studies and regulatory submissions on track. Balance sheet strengthened by $14 million equity raise.
CapsoVision Transcript: The 38th Annual Roth Conference
CapsoVision highlighted its AI-powered capsule endoscopy platform, targeting major GI markets with a robust pipeline for colon, pancreas, esophagus, and stomach imaging. Strategic partnerships and recent financing support expansion and R&D through 2026.
CapsoVision Announces $14 Million Private Placement Financing
Reports Preliminary, Unaudited Fourth-Quarter and Full Year 2025 Financial Results Reports Preliminary, Unaudited Fourth-Quarter and Full Year 2025 Financial Results
CapsoVision to Release Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 26, 2026
SARATOGA, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solution...
CapsoVision to Participate in the Benchmark 14th Annual Discovery Investor Conference
SARATOGA, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions...
CapsoVision Earnings Call Transcript: Q3 2025
Q3 2025 saw 19% revenue growth, strong adoption of CapsoCam Plus, and pipeline expansion with FDA submissions for AI and pancreatic cancer screening. IPO proceeds boosted cash reserves, while a one-time R&D charge impacted net loss.
CapsoVision to Release Third Quarter 2025 Financial Results on Thursday, November 13, 2025
Conference Call Scheduled for Thursday, November 13, 2025 at 4:30 pm ET Conference Call Scheduled for Thursday, November 13, 2025 at 4:30 pm ET
CapsoVision Earnings Call Transcript: Q2 2025
Q2 2025 revenue grew 17% year-over-year to $3.3M, with gross margin at 55% and net loss improving to $4.6M. Over 143,000 patients have used the capsule, and new FDA clearances plus an IPO and Canon partnership support future growth.
CapsoVision to Release Second Quarter 2025 Financial Results on Thursday, August 14, 2025
- Conference Call Scheduled for Thursday, August 14, 2025 at 4:30 pm ET - SARATOGA, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology comp...
CapsoVision Announces Closing of Initial Public Offering
SARATOGA, Calif., July 03, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) tech...
CapsoVision Announces Pricing of Initial Public Offering
SARATOGA, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) tech...
Medical device maker CapsoVision files for a $30 million IPO
CapsoVision, which makes a capsule endoscope system for diagnostic and screening applications, filed on Friday with the SEC to raise up to $30 million in an initial public offering.
CapsoVision IPO Registration Document (S-1)
CapsoVision has filed to go public with an IPO on the NASDAQ.